<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857230</url>
  </required_header>
  <id_info>
    <org_study_id>FSG-01-01</org_study_id>
    <nct_id>NCT03857230</nct_id>
  </id_info>
  <brief_title>The Safety and Pharmacokinetics of Primapur and Gonal-f</brief_title>
  <official_title>Study of Safety, Tolerance and Pharmacokinetics of Primapur and Gonal-f Upon Single-dose Subcutaneous Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVFarma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NADIM LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVFarma LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current phase I study was to establish bioequivalence, safety, and
      tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in
      comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young
      female volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, prospective, randomized, open-label, crossover, 2-period, two treatment, clinical
      study in healthy female volunteers.

      Objectives of the study:

        1. To evaluate the frequency and severity of adverse events (AE) following a single 300 IU
           subcutaneous injection of Primapur (IVFarma, LLC, Russia) and Gonal-F (Merck Serono
           S.p.A., Italy) to healthy volunteers.

        2. To determine the AUC0-t value of Primapur following a single 300 IU subcutaneous
           injection to healthy volunteers.

        3. To determine the T½ value of Primapur following a single 300 IU subcutaneous injection
           to healthy volunteers.

        4. To determine the Сmax value of Primapur following a single 300 IU subcutaneous injection
           to healthy volunteers.

        5. To determine the Tmax value of Primapur following a single 300 IU subcutaneous injection
           to healthy volunteers.

        6. To compare the obtained pharmacokinetic characteristics of Primapur and Gonal-F.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Actual">May 10, 2016</completion_date>
  <primary_completion_date type="Actual">May 10, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))</measure>
    <time_frame>0-192 hours</time_frame>
    <description>Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)</measure>
    <time_frame>0-192 hours</time_frame>
    <description>Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)</measure>
    <time_frame>0-192 hours</time_frame>
    <description>Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)</measure>
    <time_frame>0-192 hours</time_frame>
    <description>Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Elimination Rate Constant (Kel)</measure>
    <time_frame>0-192 hours</time_frame>
    <description>Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Area Under Curve</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Absorption</condition>
  <arm_group>
    <arm_group_label>Sequence A: Primapur - Gonal-F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B: Gonal-F - Primapur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Primapur)</intervention_name>
    <description>During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.
Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.</description>
    <arm_group_label>Sequence A: Primapur - Gonal-F</arm_group_label>
    <arm_group_label>Sequence B: Gonal-F - Primapur</arm_group_label>
    <other_name>Follitropin alpha</other_name>
    <other_name>Follitropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Gonal-F)</intervention_name>
    <description>During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.
Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.</description>
    <arm_group_label>Sequence A: Primapur - Gonal-F</arm_group_label>
    <arm_group_label>Sequence B: Gonal-F - Primapur</arm_group_label>
    <other_name>Follitropin alpha</other_name>
    <other_name>Follitropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female volunteers aged 18 to 40 years.

          2. Body mass index (BMI) of 18.5 to 30.0 kg/m2.

          3. Subjects who have used oral contraceptives for at least 2 menstrual cycles before
             study entry.

          4. Regular menstruation cycle (24 to 35 days) before initiation of oral contraception.

          5. Presence of both ovaries.

          6. Subjects who are negative for drugs of abuse and alcohol tests at screening.

          7. Subjects who are healthy as validated by pre study medical history, physical
             examination.

          8. Subjects with acceptable clinical laboratory test results.

          9. A signed informed consent form that confirms in writing the volunteer's consent to
             participate in this clinical study and the volunteer's willingness to comply with all
             physician recommendations and protocol limitations for the time of participation in
             the clinical study.

         10. Ability to comply with the requirements of the protocol.

         11. Participants in the study, as well as their sexual partners, are knowledgeable and
             willing to voluntarily, starting from the week before being included in the study and
             up to 4 weeks after the last dose of the study drug, and in addition to the
             contraceptive used, use at least 1 barrier contraceptive method or spermicide.

        Exclusion Criteria:

          1. Hypersensitivity to follitropin alpha, combined oral contraceptive (ethinylestradiol
             and drospirenone) or excipients.

          2. Allergy, angioedema (hereditary or idiopathic) in history.

          3. Previous history of ovarian hyperstimulation syndrome (OHSS).

          4. Inability to establish a venous catheter for blood sampling.

          5. Presence of polycystic ovaries (PCO) and ovarian cysts.

          6. Neoplasia and a history of malignant disease.

          7. Deep vein thrombosis, pulmonary embolism.

          8. Subjects with impaired thyroid function.

          9. Regular usage or administration of any drugs, including non-prescription drugs,
             vitamins, homeopathic remedies and dietary supplements, less than 2 weeks before the
             study (with the exception of contraceptive pills).

         10. Admission less than 2 months before the start of the study of drugs that have a
             pronounced effect on hemodynamics, liver function, and medication contained follicle
             stimulating hormone (FSH), luteinizing hormone (LH), chorionic gonadotropin (hCG),
             clomiphene, gonadotropin-releasing hormone (GnRH) analogues.

         11. Cardiovascular, bronchopulmonary, nervous, endocrine systems, gastrointestinal tract,
             liver, kidney, hematopoietic, immune systems, mental diseases.

         12. Acute infectious diseases less than 4 weeks before the start of the study.

         13. Systolic pressure less than 100 mm or above 130 mm Hg; diastolic pressure less than 70
             mm or above 90 mm Hg; heart rate less than 60 or more than 80 beats/min.

         14. Blood donation less than 3 months before the start of the study.

         15. Participation in clinical studies of drugs less than 3 months before the start of the
             present study.

         16. More than 5 alcohol units per week (1 unit is equal to 50 ml of a strong alcoholic
             drink, 200 ml of dry wine or 500 ml of beer) or anamnestic information about
             alcoholism, drug addiction, drug abuse.

         17. Smoking more than 5 cigarettes/day.

         18. Narcomania, alcoholism.

         19. Presence of pregnancy.

         20. Lactating.

         21. Any reason that, in the opinion of the investigator, could interfere with safety of
             the subject or interfere with the objectives of the study.

         22. Subjects with a lactose intolerance, lactase deficiency or glucose-galactose
             malabsorption.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan G Gordeev, D.Sc., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>O.M. Filatov Municipal Clinical Hospital N 15</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>O.M. Filatov Municipal Clinical Hospital N 15</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.30906/0869-2092-2017-80-4-13-17</url>
    <description>Link to a publisher site with a full-text article</description>
  </link>
  <results_reference>
    <citation>Tyul'kina EE, Gordeev IG, Grebenkin DYu, Kazei VA, Tsikarishvili MM, Luchinkina EE, et al. Randomized crossover comparative study of safety, tolerance and pharmacokinetics of Primapur vs. Gonal-f upon single-dose subcutaneous administration in healthy volunteers. Eksperimental'naya i Klinicheskaya Farmakologiya. 2017; 80(4): 13-17 (in Russian).</citation>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <results_first_submitted>March 13, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>follitropin alfa</keyword>
  <keyword>follicle stimulating hormone</keyword>
  <keyword>hormones, hormone substitutes, and hormone antagonists</keyword>
  <keyword>physiological effects of drugs</keyword>
  <keyword>biosimilar</keyword>
  <keyword>bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03857230/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Duration of participation was about 73 days: screening period (up to 7 days), preparation period (up to 28 days), the 1st period (9 days), the 2nd period (9 days), and the follow-up period (28 days starting from the first day of the 2nd period). The wash-out period is 10 days.</recruitment_details>
      <pre_assignment_details>28 healthy female volunteers aged 18 to 40 years inclusively have been enrolled according to the inclusion and non-inclusion criteria, among them 4 back-ups enrolled in the study to replace the volunteers excluded before the study completion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A: Primapur - Gonal-F</title>
          <description>Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.</description>
        </group>
        <group group_id="P2">
          <title>Sequence B: Gonal-F - Primapur</title>
          <description>Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Primapur-Gonal-F)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (Gonal-F-Primapur)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Women aged 18 to 40 years; body mass index (BMI) of 18.5 to 30 kg/m2</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence A: Primapur - Gonal-F</title>
          <description>Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.</description>
        </group>
        <group group_id="B2">
          <title>Sequence B: Gonal-F - Primapur</title>
          <description>Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Periods 1 and 2</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.92" spread="4.27"/>
                    <measurement group_id="B2" value="26.58" spread="3.12"/>
                    <measurement group_id="B3" value="28.25" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg per m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.41" spread="3.53"/>
                    <measurement group_id="B2" value="22.41" spread="2.80"/>
                    <measurement group_id="B3" value="22.91" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))</title>
        <description>Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.</description>
        <time_frame>0-192 hours</time_frame>
        <population>Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))</title>
          <description>Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.</description>
          <population>Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.</population>
          <units>mIU*h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1202.85" spread="466.28"/>
                    <measurement group_id="O2" value="1241.01" spread="418.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical comparison of the obtained results comprised the calculation of parametric bilateral 90 % CIs for the ratios of the corresponding mean values of the pharmacokinetic parameters of the study and comparator drug. The equivalence of the pharmacokinetics of the drug products will be proven if the limits of the evaluated CIs for the ratios of the mean values are in the range of 80.00-125.00%.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 90% CIs of the ratios of geometric means of log-transformed baseline AUC0-192 were used to assess bioequivalence between Primapur and Gonal-F (bioequivalence range of 80.00% to 125.00%)</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Geometric Mean Ratio (%)</param_type>
            <param_value>93.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.25</ci_lower_limit>
            <ci_upper_limit>99.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)</title>
        <description>Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
        <time_frame>0-192 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primapur</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)</title>
          <description>Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
          <units>mIU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.32" spread="4.72"/>
                    <measurement group_id="O2" value="16.00" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 90% CIs of the ratios of geometric means of log-transformed baseline Cmax were used to assess bioequivalence between Primapur and Gonal-F (bioequivalence range of 80.00% to 125.00%)</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Geometric Mean Ratio (%)</param_type>
            <param_value>87.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.85</ci_lower_limit>
            <ci_upper_limit>93.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)</title>
        <description>Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
        <time_frame>0-192 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primapur</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)</title>
          <description>Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.70" spread="5.77"/>
                    <measurement group_id="O2" value="19.22" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)</title>
        <description>Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
        <time_frame>0-192 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primapur</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)</title>
          <description>Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
          <units>hours</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.78" spread="32.54"/>
                    <measurement group_id="O2" value="71.71" spread="33.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Elimination Rate Constant (Kel)</title>
        <description>Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
        <time_frame>0-192 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primapur</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F</title>
            <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel)</title>
          <description>Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.</description>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.003"/>
                    <measurement group_id="O2" value="0.01" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the study day 1 to day 56.</time_frame>
      <desc>An adverse event was defined as any adverse event that began following the first dose of follitropin alfa administration till the end of follow-up period. Adverse events were reported from the 1st period (9 days), wash out period (10 days), 2nd period (9 days) and follow-up period (28 days).</desc>
      <group_list>
        <group group_id="E1">
          <title>Primapur</title>
          <description>All subjects who received a single subcutaneous injection of 300 IU Primapur.</description>
        </group>
        <group group_id="E2">
          <title>Gonal-F</title>
          <description>All subjects who received a single subcutaneous injection of 300 IU Gonal-F.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laboratory investigations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>General Manager</name_or_title>
      <organization>IVFarma LLC</organization>
      <phone>+7(499)6455342 ext 1</phone>
      <email>info@ivfarma.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

